Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
- PMID: 11396439
- DOI: 10.1056/NEJM200106073442301
Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
Abstract
Background: We tested the safety of a nonviral somatic-cell gene-therapy system in patients with severe hemophilia A.
Methods: An open-label, phase 1 trial was conducted in six patients with severe hemophilia A. Dermal fibroblasts obtained from each patient by skin biopsy were grown in culture and transfected with a plasmid containing sequences of the gene that encodes factor VIII. Cells that produced factor VIII were selected, cloned, and propagated in vitro. The cloned cells were then harvested and administered to the patients by laparoscopic injection into the omentum. The patients were followed for 12 months after the implantation of the genetically altered cells. An interim analysis was performed.
Results: There were no serious adverse events related to the use of factor VIII-producing fibroblasts or the implantation procedure. No long-term complications developed, and no inhibitors of factor VIII were detected. In four of the six patients, plasma levels of factor VIII activity rose above the levels observed before the procedure. The increase in factor VIII activity coincided with a decrease in bleeding, a reduction in the use of exogenous factor VIII, or both. In the patient with the highest level of factor VIII activity, the clinical changes lasted approximately 10 months.
Conclusions: Implantation of genetically altered fibroblasts that produce factor VIII is safe and well tolerated. This form of gene therapy is feasible in patients with severe hemophilia A.
Comment in
-
Gene therapy for hemophilia.N Engl J Med. 2001 Jun 7;344(23):1782-4. doi: 10.1056/NEJM200106073442309. N Engl J Med. 2001. PMID: 11396447 No abstract available.
Similar articles
-
Gene therapy for hemophilia.N Engl J Med. 2001 Jun 7;344(23):1782-4. doi: 10.1056/NEJM200106073442309. N Engl J Med. 2001. PMID: 11396447 No abstract available.
-
Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia.Gene Ther. 1995 Dec;2(10):736-42. Gene Ther. 1995. PMID: 8750013
-
Clinical gene transfer studies for hemophilia A.Semin Thromb Hemost. 2004 Apr;30(2):249-56. doi: 10.1055/s-2004-825638. Semin Thromb Hemost. 2004. PMID: 15118936 Review.
-
[Molecular genetics of hemophilia A].Medicina (B Aires). 1996;56(5 Pt 1):509-17. Medicina (B Aires). 1996. PMID: 9239887 Review. Spanish.
-
Gene therapy of hemophilia.Semin Thromb Hemost. 2001 Aug;27(4):417-24. doi: 10.1055/s-2001-16894. Semin Thromb Hemost. 2001. PMID: 11547364 Review.
Cited by
-
Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.J Genet Syndr Gene Ther. 2011 Dec 23;S1:007. J Genet Syndr Gene Ther. 2011. PMID: 22737594 Free PMC article.
-
Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.Gene Ther. 2013 Jun;20(6):607-15. doi: 10.1038/gt.2012.76. Epub 2012 Sep 20. Gene Ther. 2013. PMID: 22996197 Free PMC article.
-
Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases.Intractable Rare Dis Res. 2016 Aug;5(3):192-201. doi: 10.5582/irdr.2016.01062. Intractable Rare Dis Res. 2016. PMID: 27672542 Free PMC article. Review.
-
Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.Blood Adv. 2019 Dec 23;3(24):4166-4176. doi: 10.1182/bloodadvances.2019000848. Blood Adv. 2019. PMID: 31851760 Free PMC article.
-
Gene therapy for hemophilia.Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):1-8. doi: 10.1182/hematology.2019000007. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808868 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
